AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data
MELODY Data Music To Companies’ Ears
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
